Dose-Ranging Phase 2b Study of MBS2320 in Participants With Methotrexate-Refractory RA
Status:
Not yet recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
Rheumatoid arthritis (RA) affects 1 percent of the population worldwide and up to 40 percent
of patients don't respond to current treatments. MBS2320, the drug being tested in this
trial, represents a new approach to treating RA, with the potential not only to reduce levels
of inflammation but to also directly prevent bone damage. The aim of this project is to test
the safety, tolerability and efficacy of MBS2320 in patients with RA in combination with an
existing treatment, methotrexate.
Approximately 224 participants with moderate to severe active RA who have not responded to
treatment with Methotrexate will be enrolled from around 45 to 55 sites around the world.
Participants will be randomly assigned to receive 1 of 3 doses of MBS2320 (5 mg, 20 mg, or 40
mg) or placebo (a "dummy" drug).
The maximum duration of study participation for a participant will be 22 weeks, which
consists of a Screening Period of up to 4 weeks, Treatment Period of 12 weeks, and a
Follow-up Period of 6 weeks.
Participants on the study will be asked to attend the hospital or clinic for regular visits
during which they will have planned study assessments to evaluate the effectiveness,
tolerability and safety of the study drug.